Aspira and Cleveland Clinic Expand AI Diagnostics Collaboration in Women’s Health

Austin-based Aspira Women’s Health and Cleveland Clinic expanded their strategic collaboration to develop AI-powered diagnostics for women’s health, including ovarian cancer and endometriosis.

The companies said on May 26 that the agreement will support biomarker discovery, translational research, clinical validation, and commercialization efforts tied to noninvasive diagnostic technologies. The collaboration combines Cleveland Clinic’s clinical research infrastructure with Aspira’s AI-enabled multiomic platform.

Under the agreement, the organizations will work on discovering and validating biomarker signatures and developing analytical models intended to improve diagnostic accuracy and clinical utility. The initiative also includes future collaboration around intellectual property, data generation, and clinical research programs.

Mike Buhle, CEO of Aspira Women’s Health, said the partnership strengthens the company’s long-term diagnostics platform strategy and expands its scientific and operational capabilities. Kevin Elias, MD, Cleveland Clinic’s Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research, said combining multiomic biomarkers with AI-driven analytics could improve precision diagnostics in women’s health.

Multiomic Diagnostics and AI Expansion

Aspira has been building a diagnostics platform centered on combining protein biomarkers, microRNA data, and patient information into AI-supported diagnostic models. The company currently markets OvaWatch and Ova1Plus under its OvaSuite portfolio for ovarian cancer risk assessment in women with adnexal masses.

The company has also expanded its molecular testing infrastructure this year as part of its endometriosis diagnostics pipeline. In February, Aspira announced a molecular lab expansion tied to development of its ENDOinform blood test program.

The Cleveland Clinic collaboration adds expanded patient sample access and clinical validation capabilities that could support future commercialization of additional diagnostic products. Todd Pappas, PhD, Chief Scientific Officer at Aspira Women’s Health, said the agreement creates a framework for large-scale biomarker discovery and AI-driven computational modeling.

Healthcare organizations have increasingly pushed AI projects beyond pilot programs into production clinical systems tied to diagnostics, imaging, and patient workflows. Recent deployments across hospital systems have focused on operational AI infrastructure and measurable clinical outcomes.

AI Diagnostics Become a Larger Healthcare Focus

AI-driven diagnostics have become a growing area of investment across healthcare and life sciences as providers and research institutions look to improve earlier disease detection and reduce invasive procedures. Research published in the National Library of Medicine has highlighted increasing use of AI models in gynecologic oncology and women’s health diagnostics.

Ovarian cancer diagnostics remain a major clinical challenge because symptoms are often detected at later stages of disease progression. Aspira said its future pipeline will continue focusing on combining microRNA and protein biomarkers with patient data to improve sensitivity and specificity in ovarian cancer detection.

Healthcare systems have also expanded AI adoption across operational and clinical environments as financial pressure and staffing shortages increase demand for automation and diagnostic support technologies.

Aspira and Cleveland Clinic said the collaboration is intended to support future applications across women’s health through scalable biomarker discovery and AI-enabled diagnostics infrastructure.